Tuesday, June 14, 2011
VIA Pharmaceuticals Inc., of San Francisco, announced dosing of the first healthy volunteers in a Phase I trial of VIA-3196, the company's orally administered, liver-directed thyroid hormone beta receptor agonist for the treatment of high LDL cholesterol and other dyslipidemias including high triglycerides and elevated Lp (a).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.